NMT1 and cancer: PCLX- 001 (Zelenirstat), the first pan-NMT inhibitor tested in humans, targeting NMT1 and NMT2, interferes with Src family kinases and energy metabolism by promoting the degradation of NDUFAF4, an essential assembly factor for respiratory complex I in cancer cells [470].